The UK and US have finalized a major commercial pact that will ensure zero duties on British drug exports being sold in the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to boost spending on drugs through the National Health Service (NHS). This move ensures that duties on these key products will remain at zero for a period of the next three years.
This deal follows previous threats to dramatically increase import taxes on branded pharmaceutical imports, with figures discussed reaching one hundred percent.
"This agreement between the Britain strengthens the international landscape for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. drug exports," an announcement said.
Trade Impact
Medicines represent one of the UK's largest export categories to the US, which is by far the primary destination for major UK drugmakers.
Statistics show that in the one-year period leading up to September, the UK exported drugs totaling £11.1bn to the US. This value represented nearly one-fifth of British export trade in that timeframe.
"This guarantee secures jobs, boosts capital expenditure and facilitates the UK to emerge as a international leader for biotech and pharma," a government official stated.
Key UK Commitments
The pact includes several key commitments from the British government:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to raise total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The amount manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. Last year, repayments were more than twenty percent.
Industry Background
This agreement follows a ongoing row between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
This friction were intensified by arguments that US patients were charged several times more for the equivalent treatments than patients in the UK and Europe.
In recent months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been announced toward US facilities.
The Science Minister stated that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
